Ali Cahid Civelek, MD
National Institutes of Health, Department of Radiology and Imaging Sciences, Division of Nuclear Medicine, USA
Dr. Civelek earned his medical degree at the Istanbul University, Istanbul School of Medicine, and a residency at Hacettepe University Medical Center, Ankara. He received a scholarship from International Atomic Energy Agency, when he completed his nuclear medicine residency and fellowship at Johns Hopkins Medical Institutions, Division of Nuclear Medicine. After his period as a post-doctoral fellow, he was recruited as a fulltime faculty at Hopkins, where he stayed until 2003. In his early years of career at Johns Hopkins he ably assisted the clinical and research programs and later, he served as director of nuclear cardiology and clinical director and the director of nuclear medicine residency program as well as the medical director of nuclear medicine technologist program. Before joining University of Louisville as the professor and director of Nuclear Medicine & PET in 2008, he was recruited by the Saint Louis University Medical School Hospital as professor and the director of Nuclear Medicine.
Before joining Nuclear Medicine Division at the NIH, Dr. Civelek spent 2 years at the section of Body MRI and MRI-PET, department of Radiology and Imaging Sciences at NIH Clinical Center. He holds a part time active staff faculty-visiting professor position at the department of Radiology, Johns Hopkins School of Medicine.
He is a fellow of the American College of Nuclear Medicine, and Fellow & Founding member of American Society of Nuclear Cardiology, and a fellow of The American College of Angiology.Dr. Civelek has trained numerous American and international physicians in nuclear medicine including nuclear cardiology and nuclear oncology. He has a worldwide reputation in nuclear medicine and lectures at medical centers in the U.S. and internationally on nuclear medicine including nuclear cardiology and nuclear oncology/PET-CT and PET-MRI. He is committed to the continued progress of Nuclear Medicine, cardiology and oncology, the development of new tumor targeting radiopharmaceuticals for imaging and therapy, and supports high quality clinical trials and patient care, safety.